Page
%P
-
Article
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR seconda...